Shares of Glenmark Pharmaceuticals jumped 10% in early trade on Friday, a day after a unit of the Indian drugmaker signed an exclusive licensing deal with U.S. peer AbbVie for its cancer treatment.

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic ...

Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a ...

Altimmune, Inc. (NASDAQ:ALT) is one of Goldman Sachs’ top penny stock picks. On June 26, the company reported positive ...

In a June 24, 2025, podcast, Goldman Sachs’ Christian Mueller-Glissmann and Alexandra Wilson-Elizondo examined the dynamics ...

Altimmune (NASDAQ:ALT – Get Free Report) ‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They ...

Although Altimmune described the results as “positive,” the press release reported that “ [t]he effects on fibrosis improvement without worsening of MASH in an ITT analysis”—a key ...

Investing.com - Altimmune (NASDAQ:ALT) shares gained Thursday after the company announced positive topline data from its 24-week Phase 2b IMPACT trial evaluating pemvidutide in metabolic ...

In other recent news, Altimmune announced positive topline data from its 24-week Phase 2b IMPACT trial evaluating pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH). The trial met ...